SignalGene Signs a Service Agreement With CroMedica for Pharmacogenomics.Business Editors & Health/Medical Writers BIOWIRE2K MONTREAL--(BW Healthwire)--Oct. 3, 2000 SignalGene Inc. (TSE See Tokyo Stock Exchange. TSE 1. See Tokyo Stock Exchange (TSE). 2. See Toronto Stock Exchange (TSE). :SGI.) today announced the signing of a service agreement with CroMedica Prime Inc., a Phase 1 clinic at Vancouver Hospital and Health Sciences Centre Vancouver Hospital and Health Sciences Centre (VHHSC) is a medical facility located in Vancouver, British Columbia. The VHHSC is the second largest hospital in Canada, with 1,900 beds and nearly 116,000 patients each year. VHHSC employs 9500 staff and utilizes 1000 volunteers. (VHHSC VHHSC Vancouver Hospital and Health Sciences Centre (Canada) ), for the provision of genotyping services under SignalGene's offering of Pharmacogenomics Services. CroMedica Prime is a joint venture between CroMedica Global Inc., the Vancouver Hospital and Health Sciences Centre, the University of British Columbia Locations Vancouver The Vancouver campus is located at Point Grey, a twenty-minute drive from downtown Vancouver. It is near several beaches and has views of the North Shore mountains. The 7. , and the BIRC BIRC Bio-Integral Resource Center BIRC Bioinformatics Research Centre Corporation. SignalGene will use its unique pharmacogenomics platform for the genotyping of drug metabolizing enzymes (DMEs) on samples collected by CroMedica Prime from participants to its clinical trials. With the amount of scientific data currently available showing that a significant proportion of the population metabolizes various drugs at a slow rate, genotyping of DMEs has become increasingly important in the clinical phases of drug development. SignalGene is the only Canadian firm with the capacity to provide pharmacogenomics services compliant with the Food and Drug Administration (FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. ) requirements for Good Laboratory Practices (GLPs). SignalGene is an integrated genomics-based drug discovery company. By combining cutting-edge technologies in pharmacogenomics, functional genomics and drug design with world-class scientific collaborations with university and hospital researchers, SignalGene is taking a leading role in the conversion of genomic information into novel diagnostic and therapeutic products for major human diseases. Current research programs target metabolic disorders (obesity), women's health (breast cancer and osteoporosis), inflammatory disorders (psoriasis) and neurodegenerative disorders (Alzheimer's disease). The Company generates short-term revenues, through its GLP-based pharmacogenomics services and technology-based discovery collaborations, while pursuing its internal research and development programs for partnering with major pharmaceutical companies. The shares of the Company are listed on the Toronto Stock Exchange Toronto Stock Exchange (TSE) Canada's largest stock exchange, trading approximately 1,200 company stocks and 33 options. under the symbol SGI. SIGNALGENE: LEADER FOR THE MEDICINE OF TOMORROW |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion